Transcriptomics

Dataset Information

0

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple mutated AML

ABSTRACT: RNA-Seq of primary human AML samples sorted based on GPR56 and CD34 expression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE129094 | GEO | 2022/03/28

REPOSITORIES: GEO

Json Xml

Similar Datasets

Transcriptomics Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple mutated AML
2022-03-26 | GSE128848 | GEO
Unknown Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden.
| S-EPMC7796342 | biostudies-literature
Unknown Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.
| S-EPMC4034537 | biostudies-literature
Unknown Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant.
| S-EPMC6826920 | biostudies-literature
Unknown Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation.
| S-EPMC7000468 | biostudies-literature
Genomics Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple mutated AML
| PRJNA529079 | ENA
Genomics Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple mutated AML
| PRJNA530126 | ENA
Unknown Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
| S-EPMC5045383 | biostudies-literature
Unknown Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
| S-EPMC4388314 | biostudies-literature
Unknown The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.
| S-EPMC7094014 | biostudies-literature